SYBX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 20:55):

Stats
Šios dienos apimtis	3 313.00
Vidutinė apimtis	139 032
Rinkos kapitalizacija	21.81M
EPS	$0 ( 2024-04-03 )
Kita pelno data	( $-0.800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0220 (1.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Dooley Mary Beth	Sell	188	Common Stock
2024-04-02	Awad Antoine	Sell	372	Common Stock
2024-03-18	Dooley Mary Beth	Sell	0	Common Stock
2024-03-18	Dooley Mary Beth	Sell	3 612	Stock Option (right to buy)
2024-03-19	Flynn James P	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
-63.36
Last 97 transactions
Buy: 6 126 214 \| Sell: 2 856 834

Synlogic Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APOP	0.931
RMRM	0.927
TLGT	0.86
AUR	0.859
PAIC	0.836
SVOK	0.83
FEYE	0.827
TDAC	0.824
SVAC	0.824
CMLF	0.824

10 Labiausiai neigiamai susiję koreliacijos
MMAC	-0.916
AMRB	-0.869
BOCH	-0.865
NETE	-0.85

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Synlogic Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$3.37M
Bruto pelnas:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2023
Pajamos:	$3.37M
Bruto pelnas:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2022
Pajamos:	$1.18M
Bruto pelnas:	$-4.49M (-380.42 %)
EPS:	$-13.57

FY	2021
Pajamos:	$1.75M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.090

Financial Reports:

No articles found.

Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.